Search

Background: Inverse psoriasis (IP) is a variant of plaque psoriasis involving flexor surfaces. A clear definition of IP is still lacking. Therapy is based on topical and systemic treatments, including classic systemic drugs and biologic agents, but a well‐defined therapeutic strategy is absent. Materials and methods: This retrospective study investigated the general characteristics of patients with IP or vulgar psoriasis and compared the effectiveness of anti‐interleukin‐17 or anti‐interleukin‐23 agents in the same groups. Second, treatment effectiveness and the demographic characteristics of IP patients treated with IL‐23 and IL‐17 inhibitors were also compared. IP patients were included if they had specific psoriatic involvement of the axillary, inguinal, or submammary lines, breast folds, antecubital and popliteal pits, intergluteal fold, and perianal area. Patients with vulgar plaque psoriasis and concomitant intertriginous involvement were included in the vulgar psoriasis cohort. Results: Patients with IP were prevalently female and treated with IL‐17 inhibitors compared to those with vulgar psoriasis. They also had a greater risk of drug discontinuation and subsequent therapeutical switch (32.1% vs. 18.1%, P = 0.002). At later time points, those with IP showed progressively slower achievement of PASI100 and 90 compared to the cohort with vulgar psoriasis. In the IP cohort, there was greater joint involvement in patients treated with an anti‐IL‐17 agent (P = 0.011), who also had a lower median age of onset (P = 0.011) compared to patients treated with an anti‐IL‐23 agent. Patients with IP treated with an anti‐IL‐23 agent initiated with a lower mean PASI and showed a slower response than patients on an anti‐IL‐17 agent. At later time points, progressively greater effectiveness of IL‐23 inhibitors was observed compared to IL‐17 inhibitors. Conclusions: Patients with IP responded less to biologic agents than those with vulgar psoriasis. In the IP cohort, IL‐17 inhibitors had a faster onset than IL‐23 inhibitors, but long‐term anti‐IL‐23 agents seem to be associated with better outcomes. [ABSTRACT FROM AUTHOR]

Background/Objectives: Patients with treated solid tumors (TST) are a highly heterogeneous and difficult-to-treat population due to the risk of disease progression/recurrence or infection. Methods: We conducted an observational, retrospective, single-center study at the Dermatology Clinic of Turin with a focus on the special population of cancer patients with psoriasis treated with biologics. Results: As of July 2023, 52 psoriatic patients with a prior/concomitant history of malignancy had taken biologic drugs. The median age was 67 years, and the median age of cancer onset was 55 years. The most common tumors were gastrointestinal cancer and melanoma. After the tumor diagnosis, 61% received an anti-IL17 drug; 37 patients continued the initiated biologic therapy, while 12 switched drugs due to secondary inefficacy. The estimated biologic DS was 55.6% at 50 months. Evidence suggests that IL-17 is a key pathogenic factor involved in tumorigenesis, resulting in a lower risk of malignancies in subjects managed with IL-17 inhibitors. Similarly, IL-23 plays a role in suppressing innate immunity and promoting tumor and metastases development. This is a consistent real-life case series that support the use of biologic drugs in patients with TST. Conclusions: IL-23 and IL-17 inhibitors, being immunomodulators rather than immunosuppressants, may be a safe option for patients in an active oncological setting and for immune-correlated adverse events. [ABSTRACT FROM AUTHOR]